Interpretation of Statutes

Union of India v. Ranbaxy Laboratories Ltd.

(2008) 7 SCC 502

Facts

Ranbaxy manufactured Pentazocine and formulations marketed under names including Fortwin.
The Central Government issued an exemption notification under the Drugs (Prices Control) Order, 1995.
The notification exempted the specified drug “manufactured by” Ranbaxy from price control up to 31 October 1999.
Ranbaxy manufactured certain quantities before the exemption expired but sold them in the market after 31 October 1999.
The Government argued that drugs sold after the expiry date had to comply with the controlled price, even if manufactured during the exemption period.
Ranbaxy argued that the exemption attached to drugs manufactured before the specified date and continued to protect those batches when marketed later.
The interpretative dispute concerned whether the cutoff applied only to manufacture or simultaneously to manufacture and sale.

Whether the exemption covered drugs manufactured by 31 October 1999 but sold later.
Whether the words “manufactured by the company” attached the exemption to the date of manufacture.
Whether a further requirement of sale before the cutoff could be read into the notification.
Whether practical commercial realities could be considered in construing an exemption notification.

An exemption notification must be interpreted according to its actual language and statutory purpose.
Courts cannot add a condition that the notification does not contain.
Even while construing exemptions carefully, courts must not ignore commercial and operational realities.
A construction producing an unworkable result should be avoided where the language clearly supports a practical interpretation.
The subject of the exemption must be identified precisely: here, the specified drug manufactured by the named company.

The notification identified:
the drug;
the manufacturer; and
the period up to which exemption was granted.
Its operative words referred to the drug manufactured by Ranbaxy.
It did not state that the drug must also be sold before 31 October 1999.
The Court recognised that manufacture and retail sale cannot always occur simultaneously.
After production, time is required for:
testing and quality control;
packaging and labelling;
distribution to wholesalers;
transportation to retailers; and
eventual sale to patients.
The Government’s interpretation would mean that a drug lawfully manufactured shortly before midnight on the final exemption date would immediately lose the exemption before it could realistically reach the market.
That would make part of the exemption commercially ineffective.
It could also create uncertainty because the printed retail price and manufacturing date were fixed when the drug was packaged.
The Court therefore connected the exemption to the relevant manufacturing date.
Drugs manufactured after expiry were subject to price control.
Drugs manufactured during the valid exemption period retained the benefit when subsequently marketed.
This did not improperly extend the duration of the notification; it merely identified which products had acquired the exemption while it operated.
The Court refused to insert the additional words “and sold” into a notification that referred only to manufacture.

The Supreme Court dismissed the Union’s appeal.
It held that drugs manufactured by Ranbaxy on or before 31 October 1999 remained exempt from price control even when sold later.
The exemption was determined by the date of manufacture, not the final retail sale.
The case demonstrates that even exemption provisions must be interpreted coherently and with attention to practical realities.
Use this case for: workable interpretation, refusal to add conditions and contextual construction of exemption notifications